JK-05

from Wikipedia, the free encyclopedia

JK-05 is an experimental antiviral that works against various RNA viruses .

properties

JK-05 is an inhibitor of viral RNA polymerase effective against influenza virus , ebola virus , yellow fever virus , various arenaviruses and bunyaviruses . JK-05 is structurally related to favipiravir and possibly identical to the patented favipiravir of the Japanese pharmaceutical company Toyama Kagaku Kōgyō . JK-05 is manufactured by Sihuan Pharmaceutical .

In the wake of the 2014 Ebola fever epidemic , JK-05 received preliminary Chinese drug approval for the treatment of Ebola virus infections.

literature

  • W. Wu, S. Liu: [Research progress of prevention and treatment of Ebola virus infection]. In: Nan fang yi ke da xue xue bao = Journal of Southern Medical University. Volume 34, Number 10, October 2014, pp. 1519-1522, PMID 25345954 .

Individual evidence

  1. ^ Adam Jourdan: China military-linked firm eyes quick approval of drug to cure Ebola . Reuters.
  2. ↑ J-CAST News: 日本 で 開 発 し た 「エ ボ ラ 特効 薬」 に パ ク リ 疑惑 中国 で 同 成分 の 薬 を 製造 と WHO が 指摘 ( Memento of November 29, 2014 in the Internet Archive ) (Japanese).
  3. ↑ Zhuang Pinghui: Ebola virus drug approved on mainland for emergency use only. South China Morning Post dated September 1, 2014.
  4. ^ Adam Jourdan: China military-linked firm eyes quick approval of drug to cure Ebola. Yahoo News, dated October 14, 2014.
  5. ↑ Frank Sieren : Beijing Develops Ebola drug DW.de of 23 October, 2014.